Fresenius stock: Jefferies keeps EUR 55.00 target for Fresenius stock

Published on 10/21/2026 at 17:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue rose 6.00 percent to EUR 5.86 billion. Fresenius stock costs EUR 45.46 on October 21, 2026, 1.02 percent above the Xetra close.

Analyst target and results

Jefferies kept its EUR 55.00 target for Fresenius on October 21, 2026.
Second-quarter 2026 revenue reached EUR 5.86 billion, up 6.00 percent year over year.
Fresenius stock costs EUR 45.46 at Lang & Schwarz on October 21, 2026 at 5:10 p.m. CEST, 1.02 percent above the Xetra close of October 21, 2026 and 14.16 percent below the 52-week high.
Fresenius is scheduled to publish third-quarter 2026 results on November 4, 2026.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius (ISIN DE000FRE5EN2) drew a EUR 55.00 price target from Jefferies on October 21, 2026, while the 14-analyst consensus target stood at EUR 55.69, according to MarketScreener. The stock was trading at EUR 45.46 at Lang & Schwarz on October 21, 2026 at 5:10 p.m. CEST, up 1.02 percent versus the Xetra close of October 21, 2026 at EUR 45.00.

Quarterly growth supports the target

Fresenius reported EUR 5,864 million of revenue for the second quarter of 2026, an increase of 6.00 percent from EUR 5,571 million in the second quarter of 2025. Core net income rose 14.00 percent to EUR 470 million from EUR 412 million, while core earnings per share increased 14.00 percent to EUR 0.83, according to Fresenius.

Stock position on October 21

The Xetra-linked market picture places the stock at EUR 45.46 against a 52-week range of EUR 35.11 to EUR 52.96 as of October 21, 2026. The current price is 14.16 percent below the 52-week high, while trading volume stood at 361,858 shares and market capitalization at EUR 25.6 billion.

Valuation and the next date

Fresenius traded at a price-to-earnings ratio of 16.55 on October 21, 2026. The next scheduled corporate date is November 4, 2026, when Fresenius is due to publish third-quarter 2026 results, according to the investor-relations calendar.

Comparison with peers

Fresenius: up 1.02 percent, price-to-earnings ratio 16.55, market capitalization EUR 25.6 billion. Siemens Healthineers (Xetra, EUR): up 0.19 percent, price-to-earnings ratio 20.98, market capitalization EUR 46.5 billion. Fresenius Medical Care (NYSE, USD): up 0.77 percent, price-to-earnings ratio 11.58, market capitalization USD 11.5 billion.

Target distance remains measurable

The Jefferies target of EUR 55.00 stands 20.98 percent above the Lang & Schwarz price of EUR 45.46 on October 21, 2026. That spread gives the analyst view a concrete valuation frame, while the 6.00 percent second-quarter revenue growth supplies an operating counterweight.

The further course of trading is shown by the continuously updated real-time quote of Fresenius stock.